PureTech Health (LON:PRTC) Trading Up 14.2% – Should You Buy?

PureTech Health plc (LON:PRTC) was up 14.2% on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares were traded during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Up 14.2%

The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The firm has a market cap of £293.65 million, a price-to-earnings ratio of 714.71 and a beta of 1.02. The firm has a 50-day moving average price of GBX 129.46 and a two-hundred day moving average price of GBX 129.72.

Insider Buying and Selling at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira bought 167,739 shares of the business’s stock in a transaction dated Thursday, July 3rd. The shares were acquired at an average price of GBX 1 per share, with a total value of £1,677.39. Company insiders own 13.13% of the company’s stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.